CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BPBRM1MutationPrognosticSupportsClear Cell Renal Cell CarcinomaHakimi et al., 2013
BVHLMutationPrognosticSupportsClear Cell Renal Cell CarcinomaHakimi et al., 2013
BEZH2MutationPrognosticSupportsPoor OutcomeMyelodysplastic SyndromeNikoloski et al., 2010
BVHLLoss-of-functionPrognosticSupportsPoor OutcomeClear Cell Renal Cell CarcinomaSchraml et al., 2002
BKMT2DLoss-of-functionDiagnosticSupportsPositiveFollicular LymphomaMorin et al., 2011
DEML4::ALKFusion AND ALK AmplificationPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2012
DAPCMutationPredictiveSupportsSensitivity/ResponseColon CarcinomaJW55Waaler et al., 2012
BASXL1MutationDiagnosticSupportsPositiveAcute Myeloid LeukemiaOhgami et al., 2015
DATMMutationPredictiveSupportsSensitivity/ResponseGlioblastomaTemozolomideEich et al., 2013
DATMMutationPredictiveSupportsSensitivity/ResponseMelanomaTemozolomideEich et al., 2013
EAURKAAmplificationPredictiveSupportsSensitivity/ResponseEsophagus AdenocarcinomaCisplatin,AlisertibSehdev et al., 2012
DAURKAOverexpressionPredictiveSupportsResistanceCervical AdenocarcinomaPaclitaxelAnand et al., 2003
BBAP1EXPRESSIONPrognosticSupportsBetter OutcomeUveal Melanomavan Essen et al., 2014
BBRAFV600EPrognosticSupportsPoor OutcomeMultiple MyelomaAndrulis et al., 2013
BBRCA1MutationPrognosticSupportsBetter OutcomeEpithelial Ovarian CancerBolton et al., 2012
BBRCA2MutationPrognosticSupportsBetter OutcomeEpithelial Ovarian CancerBolton et al., 2012
BEGFRAmplificationPrognosticSupportsPoor OutcomeBarrett's AdenocarcinomaMarx et al., 2010
BEGFRAmplificationPrognosticSupportsPoor OutcomeCervical Squamous Cell CarcinomaIida et al., 2011
BEGFROverexpressionPrognosticSupportsPoor OutcomeBrain Glioblastoma MultiformeShinojima et al., 2003
BTMPRSS2::ERGFusionDiagnosticSupportsPositiveProstate CarcinomaTomlins et al., 2005
BFGFR3Y373CDiagnosticSupportsPositiveBladder CarcinomaBodoor et al., 2010
BNCOA3AMPLIFICATIONPrognosticSupportsPoor OutcomeBreast CancerBurandt et al., 2013
BNCOA3OVEREXPRESSIONPrognosticSupportsPoor OutcomeBreast CancerBurandt et al., 2013
BNOTCH1MutationPrognosticSupportsPoor OutcomeMantle Cell LymphomaKridel et al., 2012
BNOTCH1P2514FSPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaFabbri et al., 2011
BNRASQ61PrognosticSupportsFollicular Thyroid CarcinomaFukahori et al., 2012
BPAX8::PPARGFusionDiagnosticSupportsPositiveFollicular Thyroid CarcinomaNikiforova et al., 2003
BPBRM1MutationPrognosticSupportsBetter OutcomeRenal Cell CarcinomaKapur et al., 2013
BPGRExpressionPrognosticSupportsBetter OutcomeBreast CancerDowsett et al., 2006
BPIK3CAAmplificationPrognosticSupportsPoor OutcomeGastric AdenocarcinomaShi et al., 2012
BPTENLossPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2011
BRUNX1MutationPrognosticSupportsPoor OutcomeAcute Lymphoblastic LeukemiaGrossmann et al., 2013
BSMAD4MutationPrognosticSupportsPoor OutcomePancreatic AdenocarcinomaBlackford et al., 2009
BTERTAmplificationPrognosticSupportsPoor OutcomeAcral Lentiginous MelanomaDiaz et al., 2014
BTERTPromoter MutationPrognosticSupportsPoor OutcomeSkin MelanomaGriewank et al., 2014
BTP53Deleterious MutationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaSkinner et al., 2012
BTP53MutationPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell CarcinomaKoch et al., 1996
BTTF1AMPLIFICATIONPrognosticDoes Not SupportLung AdenocarcinomaBarletta et al., 2009
BIKZF1DeletionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomavan der Veer et al., 2014
BIKZF1DeletionPrognosticSupportsPoor OutcomeAcute Lymphoblastic LeukemiaMartinelli et al., 2009
BIKZF1DeletionPrognosticSupportsPoor OutcomeAcute Lymphoblastic LeukemiaKuiper et al., 2010
BIDH2R172PrognosticDoes Not SupportBetter OutcomePeripheral T-cell LymphomaWang et al., 2015
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaPonatinibTanneeru et al., 2013
CATMS2289*PredictiveSupportsSensitivity/ResponseProstate CancerOlaparibMateo et al., 2015
CATMN2875HPredictiveSupportsSensitivity/ResponseProstate CancerOlaparibMateo et al., 2015
CNF2Y177fsPredictiveSupportsResistancePeritoneal MesotheliomaCisplatin,CarboplatinSheffield et al., 2015
DPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHirota et al., 2003
DPDGFRAV561APredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHirota et al., 2003
BTERTPromoter MutationDiagnosticSupportsPositiveThyroid CancerLiu et al., 2013
BTERTPromoter MutationPrognosticSupportsPoor OutcomeThyroid CancerLiu et al., 2013
Page 29 of 96
PreviousNext